Evidence map›Paper›PMID 38991109›Full record

ArticleAIDS care2024

Evaluation of rapid antiretroviral initiation strategy in a cohort of newly diagnosed people living with HIV in Panama, 2018-2019.

Juan Pablo Alvis-Estrada, Andrés Azmitia-Rugg, Ximena Sobalvarro-Stolz, Daniela Romo-Dueñas, Félix Díaz, Alexander Martínez, Rosa Elena Morales, Lissette Raquel Chang, Natalia Vega, Ana Belén Araúz and 1 more

Abstract read
In one paragraph

Article in AIDS care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Juan Pablo Alvis-EstradaJuan Pablo Alvis-Estrada, Centro de Estudios en Salud, Universidad del Valle de Guatemala, Guatemala City, Guatemala.
Andrés Azmitia-RuggAndrés Azmitia-Rugg, Center for Disease Control and Prevention (CDC) Central America Region, Guatemala City, Guatemala.
Ximena Sobalvarro-StolzXimena Soblavarro-Stolz, Centro de Estudios en Salud, Universidad del Valle de Guatemala, Guatemala City, Guatemala.
Daniela Romo-DueñasDaniela Romo-Dueñas, Centro de Estudios en Salud, Universidad del Valle de Guatemala, Guatemala City, Guatemala.
Félix DíazFélix Diaz, Hospital Santo Tomás, Panama City, Panama.
Alexander MartínezAlexander Martinez, Instituto Conmemorativo Gorgas de Estudios en Salud, Panama City, Panama.
Rosa Elena MoralesRosa Elena Morales, Center for Disease Control and Prevention (CDC) Central America Region, Guatemala City, Guatemala.
Lissette Raquel ChangLissette Raquel Chang, Center for Disease Control and Prevention (CDC) Central America Region, Panama City, Panama.
Natalia VegaNatalia Vega, Centro de Estudios en Salud, Universidad del Valle de Guatemala, Guatemala City, Guatemala.
Ana Belén AraúzAna Belén Araúz, Instituto Conmemorativo Gorgas de Estudios en Salud, Panama City, Panama.
Gustavo Ávila-MontesGustavo Ávila-Montes, Centro de Estudios en Salud, Universidad del Valle de Guatemala, Guatemala City, Guatemala.

Funding

CGH CDC HHS U2G GH001285
6 · The paper itself

Abstract

Antiretroviral therapy (ART) has been adopted as a form of HIV treatment and prevention. This study assesses rapid ART initiation using clinical outcomes such as viral load (VL) and CD4+ T lymphocytes count. Over the course of one year, the progress of newly diagnosed people living with HIV who started ART early in a hospital in Panama City was followed. The evaluation of early initiation of ART in achieving viral suppression (VL <200 copies/ml) was analyzed using descriptive statistics. Additionally, the cost difference between early (first 7 days) and late initiation of ART was evaluated from the perspective of the service provider. In total, 209 people were followed up during the study; 85% were male, 70% started ART on same day from hospital arrival, 80% had suppressed viral load at 6 months, and the median count of CD4 increased from 285 (IQR: 166-429) to 509 (IQR: 373-696) over 12 months. Starting ART early led to a 42% increase for the provider in terms of staffing costs; however, the clients had the opportunity to decrease absenteeism in daily activities. The results reveal that early initiation of ART generates clinical and economic benefits for the person in treatment.

Indexed as

Anti-HIV AgentsHIV InfectionsViral LoadAdultCD4 Lymphocyte CountFemaleHumansMaleMiddle AgedPanamaTime-to-TreatmentTreatment OutcomeAnti-HIV Agentsantiretroviral therapyearly initiationHealthcare and well-beingHIVpartnerships for the goalsreduced inequalities

Identifiers

PMID38991109
PMCPMC11511629

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.